Clinical trial
Multicenter, Double-Blind, Randomized, Comparative Efficacy and Safety Study of MYL-1401H and European Sourced Neulasta® in Stage II/III Breast Cancer Patients Receiving Neoadjuvant or Adjuvant Chemotherapy
NCT02467868 is registered in ClinicalTrials.gov with Mylan Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Multicenter, Double-Blind, Randomized, Comparative Efficacy and Safety Study of MYL-1401H and European Sourced Neulasta® in Stage II/III Breast Cancer Patients Receiving Neoadjuvant or Adjuvant Chemotherapy
- Lead sponsor
- Mylan Inc.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- March 31, 2015
- Completion date
- February 29, 2016
- Enrollment
- 193 (actual)
- Sites
- 36
Conditions
As the registry lists them; a condition with its own page is linked.